Physician profile
Michelle Simonelli
NPI 1760993422
$991.24
in general payments reported to CMS, 2019-2025
18 companies · $307 in 2025
The $307 reported for 2025 was more than what 85% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.72 · 2022: $152 · 2023: $172 · 2024: $344 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $218.01 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $166.80 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $106.61 | 2022-2025 | Bexsero, Penmenvy |
| Sanofi Pasteur INC. | $103.88 | 2022-2024 | |
| Cranial Technologies, INC | $72.83 | 2022-2024 | Doc Band |
| Kaleo, INC. | $46.33 | 2024 | Auvi-Q |
| Organon LLC | $34.66 | 2023 | Nexplanon |
| Cognoa, INC. | $32.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.54 | 2023-2025 | Rotateq, M-M-R II, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $28.22 | 2024 | |
| Alk-Abello, INC | $22.16 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $21.72 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $21.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.63 | 2023 | Flumist Quadrivalent |
| Neos Therapeutics, LP | $18.50 | 2024 | Adzenys Xr-Odt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.70 | 2022 | |
| Seqirus USA INC | $15.79 | 2023 | Flucelvax Quadrivalent |
| Tris Pharma INC | $13.93 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Simonelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.